comparemela.com

Liean Schenck News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash. | March 27, 2023

United statesDaniel oconnellDerek meisnerAlex braunDerrell porterLiean schenckAtara biotherapeutics incAcumen pharmaceuticals incClinical developmentCompany phaseExchange commissionDevelopment rd expensesDrug administrationDanielo connellChief executive officerBusiness highlights

Acumen Pharmaceuticals, Inc (ABOS) Q2 2022 Earnings Call Transcript

ABOS earnings call for the period ending June 30, 2022.

San diegoUnited statesLiean schenckMatt zugaJohn woolfordEli lillyPaul matteisGeoff meachamAmerica merrill lynchDaniel oconnellKent iversonTom shraderJeff sevignyDan oconnellLonza biologicsJudah frommer

vimarsana © 2020. All Rights Reserved.